von Tobias Borgers | Jan. 19, 2023 | Bayer
Pharmaindustrie Bayer verlagert Pharma-Fokus in die USA und nach China Den europäischen Standort betrachtet Bayer-Pharmachef Oelrich als „innovationsunfreundlich“. Bayer wolle sich nun stärker auf China und die USA konzentrieren. Bayer kritisiert das Umfeld für...
von Tobias Borgers | Jan. 19, 2023 | Bayer
Bayer erwartet von neuem Gerinnungshemmer Boost für Pharma-Pipeline Frankfurt (Reuters) – Bayer erhofft sich von seinem neuen Gerinnungshemmer Asundexian kräftigen Rückenwind für sein Pharmageschäft. Der Pharma- und Agrarkonzern hob am Dienstag seine Prognose...
von Tobias Borgers | Jan. 19, 2023 | Boehringer
INGELHEIM, Germany and SOUTH SAN FRANCISCO, Calif., Jan. 9, 2023 /PRNewswire/ — Boehringer Ingelheim and 3T Biosciences, today announced they have entered into a strategic collaboration and licensing agreement to discover and develop next-generation cancer...
von Tobias Borgers | Jan. 19, 2023 | Bayer
AskBio Announces Strategic Collaboration with ReCode Therapeutics to Explore Single Vector Gene Editing Platform Research Triangle Park, N.C. (January 9, 2023) – Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned and independently operated subsidiary of...
von Tobias Borgers | Jan. 19, 2023 | Boehringer
BERLIN, Germany, January 10, 2023 / B3C newswire / — ProBioGen announced today a new non-exclusive collaboration with Boehringer Ingelheim on ProBioGen’s DirectedLuck® transposase technology.
ProBioGen and Boehringer Ingelheim have a long legacy...
von Tobias Borgers | Dez. 28, 2022 | Boehringer
Occuity, the fast-growing Reading-based Medtech has signed a preliminary agreement with world leading research-driven pharmaceutical company, Boehringer Ingelheim, to enter its start-ups acceleration program, to develop exploit Occuity’s patented glucose monitoring...
